



Emerald Health Therapeutics Grants Options to Executive

VICTORIA, BC. March 6, 2018 – Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) (Emerald) issued 120,000 incentive stock options to Paul Dillman, VP Marketing and Sales. The options are exercisable for a period of five years at a price equal to the closing price of the common shares on the TSX Venture Exchange on the date before their issuance. The options vest over three years with 25% vesting on the date of grant and 25% on each of the first three anniversaries of the date of grant, provided that Mr. Dillman continues to provide services to Emerald on the date of each vesting increment. The Options have been granted pursuant to the Company's Omnibus Incentive Plan which has been previously approved by the Company's shareholders and the TSX Venture Exchange.

About Emerald Health Therapeutics

Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) operates through Emerald Health Therapeutics Canada Inc. ("EHTC"), a wholly owned subsidiary and Licensed Producer under Canada's Access to Cannabis for Medical Purposes Regulations. Through EHTC, Emerald is authorized to produce and sell dried cannabis and cannabis oil for medical purposes. It operates an indoor facility in Victoria, BC, and is building a 500,000 ft² greenhouse on 32 acres in Metro Vancouver, with expansion potential to 1 million ft² to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald owns 50% of a Joint Venture with Village Farms International, Inc. that is converting an existing 1.1 million ft² greenhouse in Delta, BC to grow cannabis. Emerald's team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald is part of the [Emerald Health Group](#), which is broadly focused on developing pharmaceutical, botanical and nutraceutical products that may provide wellness and medical benefits by interacting with the human body's endocannabinoid system.

Please visit www.emeraldhealth.ca for more information or contact:

Robert Hill
CFO
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Ray Lagace
Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Contact Information: invest@emerald.care

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."